Skip to content
Metabolic & WeightGrade DWeak, conflicting or negative3 primary sources

SLU-PP-332

Also known as ERR agonist SLU-PP-332

A small molecule, not a peptide, promoted as an "exercise in a pill". All published data is from mice; nothing has been tested in humans.

Overview

Endurance exercise switches on a family of genes that build more mitochondria and shift muscle toward burning fat. A group of nuclear receptors called ERRs sit near the top of that programme. SLU-PP-332 activates them directly. In mice this increased running endurance and reduced fat gain on a high-fat diet without the animals exercising. No human has taken it in a published trial.

Research areas

Exercise mimeticsMitochondrial biogenesisObesity

Community-specified data

Community dosage information

Unverified
Community protocol

SLU-PP-332 5mg

Third-party
01Reconstitution solution
1 mL
02Dose
0.5 mg
03Syringe units
10 units
04Frequency
7x/week
05Cycle length
90 days
06Bacteriostatic water
1 mL
07Bottle size
5 mg
08Bottles needed
9

Source note: Can bump to 1000mcg -> 1500 -> 2000mcg

Track this schedule
Community protocol

SLU-PP-332 30mg

Third-party
01Reconstitution solution
3 mL
02Dose
0.5 mg
03Syringe units
5 units
04Frequency
7x/week
05Cycle length
90 days
06Bacteriostatic water
3 mL
07Bottle size
30 mg
08Bottles needed
2

Source note: Can bump to 1000mcg -> 1500 -> 2000mcg

Track this schedule

Not medical guidance. These third-party figures have not been independently verified, clinically reviewed, or endorsed by DB Peptide. They may be inaccurate or unsafe and should not replace product labelling or advice from a qualified clinician.

Dosing reported in the literature

Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.

Protocol as reportedSource
Intraperitoneal SLU-PP-332 in mice, with endurance and metabolic endpoints measured over days to weeksRodent only. No human dose can be inferred from this.Billon et al., Journal of Pharmacology and Experimental Therapeutics 2023

Trial status

No human trials of any phase. All data is preclinical.

Reported safety signals

  • No human safety data exists at any dose.
  • ERR receptors are expressed in heart, liver and kidney as well as muscle, so systemic agonism is not muscle-selective.
  • Sold through research-chemical channels with no verification of identity or purity.

Common questions

Does it replace exercise?

No, and nothing has shown that it does in a human. In mice it reproduces part of the muscle gene programme that endurance training induces. Exercise also affects cardiovascular, skeletal, cognitive and metabolic systems in ways a single nuclear-receptor agonist does not.

Primary sources

3 citations
  1. 01

    A synthetic ERR agonist alleviates metabolic syndrome

    Journal of Pharmacology and Experimental Therapeutics2023

  2. 02

    Estrogen-related receptors: novel potential regulators of exercise-induced adaptations

    Physiological Reviews2015

  3. 03

    Synthetic ERR agonists as exercise mimetics

    Cell Chemical Biology2024

Medical disclaimer

This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.

How this profile was built →